Monografias.com > Uncategorized
Descargar Imprimir Comentar Ver trabajos relacionados

Los peligros de los anticonceptivos y su uso en la mujer transexual (página 2)


Partes: 1, 2

  • 5. Dahlbäck B, Carlsson M,
    Svensson PJ. Familial thrombophilia due to a previously
    unrecognised mechanism characterized by poor anticoagulant
    response to activated protein C: prediction of a cofactor to
    activated protein C. Proc Natl Acad Sci USA 1993; 90:
    1004-8.

  • 6. Bloemenkamp KWM, Rosendaal FR,
    Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement
    by factor V Leiden mutation of risk of deepvein thrombosis
    associated with oral contraceptives containing a
    thirdgeneration progestagen. Lancet 1995; 346:
    1593-6.

  • 7. Blom JW, Doggen CJ, Osanto S,
    Rosendaal FR. Old and new risk actors for upper extremity
    deep venous thrombosis.JThromb
    Haemost2005;3:2471-8.

  • 8. Borrego L, Gil R, Mazuecos A.
    Cholesterol embolism to the skin. Clin Exp Dermatol
    1992;17:424-6.

  • 9. Boston Collaborative Drug
    Surveillance Program. Oral contraceptives and venous
    thromboembolic disease, surgically confirmed gall bladder
    disease and breast tumours. Lancet 1973; i:
    1399-404.

  • 10. Dahlberg PJ, Frecentese DF,
    Cogbill TH. Cholesterol embolism: experience with 22
    histologically proven cases. Surgery 1989;
    105:737-46.

  • 11. Daly E, Vessey MP, Hawkins MM,
    Carson JL, Gough P, Marsh S. Risk of venous thromboembolism
    in users of hormone replacement therapy. Lancet 1996; 348:
    977-80.

  • 12. De Bruijn SF, Stam J,
    Vandenbroucke JP. Increased risk of cerebral venous sinus
    thrombosis with third-generation oral contraceptives.
    Cerebral Venous Sinus Thrombosis Study Group. Lancet 1998;
    351:1404.

  • 13. Del Río E,
    Vázquez Veiga H, Martín de Hijas C, Gorospe MA,
    Sánchez Yus E. Necrosis cutánea por
    embolización de cristales de colesterol. Actas
    Dermosifiliogr 1993;84:303-6..

  • 14. Dinger JC, Heinemann LA,
    Kuhl-Habich D. The safety of a drospirenone-containing oral
    contraceptive: final results from the European Active
    Surveillance Study on oral contraceptives based on 142,475
    women-years of observation.Contraception
    2007;75:344-54.

  • 15. Dittrich R, Binder H, Cupisti
    S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of
    male-to-female transsexuals using gonadotropin-releasing
    hormone agonist. Exp Clin Endocrinol Diabetes 2005;
    113:586-92.

  • 16. Drife JO. The third generation
    pill controversy (continued). BMJ 2001;
    323:119-20.

  • 17. Farmer RD, Lawrenson RA,
    Thompson CR, Kennedy JG, Hambleton IR. Population-based study
    of risk of venous thromboembolism associated with various
    oral contraceptives. Lancet 1997; 349: 83-8.

  • 18. Farmer RD, Todd JC, MacRae KD,
    Williams TJ, Lewis MA. Oral contraception was not associated
    with venous thromboembolic disease in recent study. Br Med J
    1998; 316: 1090-1.

  • 19. Fine MJ, Kapoor W, Falanga V.
    Cholesterol crystal embolization: a review of 221 cases in
    the English literature. Angiology 1987;38:769-84

  • 20. Flory CM. Arterial occlusions
    produced by emboli from eroded aortic atheromatous plaques.
    Am J Pathol 1945; 21: 549-64.

  • 21. Futterweit
    WTerapia de la transexualidad y las
    complicaciones potenciales. Archives of Sexual Behavior
    1998; 27: 209-226

  • 22. Gallo MF, Lopez LM, Grimes DA,
    Schulz KF, Helmerhorst FM. Combination contraceptives:
    effects on weight.Cochrane Database Syst
    Rev2008;(4):CD003987.

  • 23. Garcia-Malpartida K,
    Martin-Gorgojo A, Rocha M, Gomez-Balaguer M,
    Hernandez-Mijares A. Prolactinoma induced by estrogen and
    cyproterone acetate in a male-to-female transsexual. Fertil
    Steril 2010;94:1097.e13-15

  • 24. Giltay EJ, Gooren LJG. Effect
    of sex steroid deprivation/administration on hair growth and
    skin sebum production in transsexual males and females. J
    Clin Endocrinol Metab 2000;85:2913-21…

  • 25. Gooren L. Hormone treatment of
    the adult transsexual patient. Horm Res 2005; 64(suppl
    2):31-6.

  • 26. Gooren LJ, Giltay EJ, Bunck
    MC. Long-term treatment of transsexuals with cross-sex
    hormones: extensive personal experience. J Clin Endocrinol
    Metab 2008; 93:19-25.

  • 27. Gooren LJG y Delemarre-van de
    Waal. Memo sobre la viabilidad de las intervenciones
    endocrinos en los transexuales de menores. Revista de
    Psicología y Sexualidad Humana 1996; 8:
    69-74

  • 28. Gregersen H. Third generation
    oral contraceptives and heritable thrombophilia as risk
    factors for non-fatal venous thromboembolism. Thromb Haemost
    1998; 79: 28-31.

  • 29. Grodstein F, Stampfer MJ,
    Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC,
    Hennekens CH. Prospective study of exogenous hormones and
    risk of pulmonary embolism in women. Lancet 1996; 348:
    983-7.

  • 30. Heinemann LAJ, Dinger JC.
    Range of published estimates of venous thromboembolism
    incidence in young women. Contraception 2007;
    75:328-36.

  • 31. Herings RMC, Urquhart J,
    Leufkens HGM. Venous thromboembolism among new users of
    different oral contraceptives. Lancet 1999;
    354:127-8.

  • 32. Hirsch DR, Mikkola KM, Marks
    PW, Fox EA, Dorfman DM, Ewenstein BM, Goldhaber SZ. Pulmonary
    embolism and deep venous thrombosis during pregnancy or oral
    contraceptive use: prevalence of factor V Leiden. Am Heart J
    1996; 131: 1145-8.

  • 33. Huisman MV, Buller HR, Ten
    Cate JW, Vreeken J. Serial impedance plethysmography for
    suspected deep venous thrombosis in outpatients. The
    Amsterdam General Practitioner Study. N Engl J Med 1986; 314:
    823-8.

  • 34. Jick H, Derby LE, Wald Myers
    M, Vasilakis C, Newton KM. Risk of hospital admission for
    idiopathic venous thromboembolism among users of
    postmenopasusal oestrogens. Lancet 1996; 348:
    981-3.

  • 35. Jick H, Jick SS, Gurewich V,
    Myers MW, Vasilakis C. Risk of idiopathic cardiovascular
    death and nonfatal venous thromboembolism in using oral
    contraceptives with differing progestagen .Lancet1995;
    346:1589-93.

  • 36. Jordan WM. Pulmonary embolism.
    Lancet 1961; i: 1146-7.

  • 37. Kamphuisen PW, Eikenboom JCJ,
    Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased
    levels of factor VIII and fibrinogen in patients with venous
    thrombosis are not caused by acute phase reactions. Thromb
    Haemost 1999; 81: 680-3.

  • 38. Kemmeren JM, Algra A, Grobbee
    DE. Third generation oral contraceptives and risk of venous
    thrombosis: meta-analysis. BMJ 2001; 323:131-4.

  • 39. Kemmeren JM, Algra A, Meijers
    JC, Bouma BN, Grobbee DE. Effects of second and third
    generation oral contraceptives and their respective
    progestagens on the coagulation system in the absence or
    presence of the factor V Leiden mutation.Thromb Haemost 2002;
    87:199-205.

  • 40. Konstantinides S. Acute
    pulmonary embolism. N Eng J Med. 2008;359:2804-13

  • 41. Koster T, Blann AD, Briët
    E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor
    VIII in effect of von Willebrand factor on occurrence of
    deep-vein thrombosis. Lancet 1995; 345: 152-5

  • 42. Kuhnz W, Staks T, Jutting G.
    Pharmacokinetics of cyproterone acetate and ethinylestradiol
    in 15 women who received a combination oral contraceptive
    during three treatment cycles.Contraception 1993;
    48:557-75.

  • 43. Lachnit-Fixson U. The
    development and evaluation of an ovulation inhibitor (DIAne)
    containing an antiandrogen.Acta Obstet Gynecol Scand
    Suppl1979;88:33-42.

  • 44. Lensing AW, Prandoni P,
    Brandjes D, Huisman PM, Vigo M, Tomasella G, Krekt J, Wouter
    TC, Huisman MV, Buller HR. Detection of deep-vein thrombosis
    by real-time B-mode ultrasonography. N Engl J Med 1989; 320:
    342-5.

  • 45. Lidegaard O, Edström B,
    Kreiner S. Oral contraceptives and venous thromboembolim. A
    case-control study.Contraception 1998; 57:291-301.

  • 46. Lopez LM, Kaptein A,
    Helmerhorst FM. Oral contraceptives containing drospirenone
    for premenstrual syndrome.Cochrane Database Syst Rev
    2009;(2):CD006586.

  • 47. Martinelli I, Taioli E,
    Bucciarelli P, Akhavan S, Mannucci PM. Interaction between
    the G20210A mutation of the prothrombin gene and oral
    contraceptive use in deep vein thrombosis. Arterioscler
    Thromb Vasc Biol 1999; 19: 700-3.

  • 48. McNeill EJM. Management of the
    transgender voice. J Laryngol Otology 2006;
    120:521-3.

  • 49. Middeldorp S, Meijers JC, Van
    den Ende AE, Van Enk A, Bouma BN, Tans G, et al. Effects on
    coagulation of levonorgestrel- and desogestrel-containing low
    dose oral contraceptives: a cross-over study. Thromb Haemost
    2000; 84:4-8.

  • 50. Moolenaar W, Lamers CB.
    Cholesterol crystal embolization in the Netherlands. Arch
    Intern Med 1996;156:653-7

  • 51. Moore E, Wisniewski A, Dobs A.
    Endocrine treatment of transsexual people: a review of
    treatment regimens, outcomes, and adverse effects. J Clin
    Endocrinol Metab 2003; 88:3467- 73.

  • 52. Muhn P, Fuhrmann U,
    Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone:
    a novel progestogen with antimineralocorticoid and
    antiandrogenic activity.Ann N Y Acad Sci1995; 761:
    311-35.

  • 53. Naess IA, Christiansen SC,
    Romundstad P, Cannegieter SC, Rosendaal FR,
    Hammerstrøm J. Incidence and mortality of venous
    thrombosis: a population-based study.J Thromb Haemost 2007;
    5:692-9.

  • 54. Oelkers W, Foidart JM,
    Dombrovicz N, Welter A, Heithecker R. Effects of a new oral
    contraceptive containing an antimineralocorticoid ,
    drospirenone, on the renin-aldosterone system, body weight,
    blood pressure, glucose tolerance, and lipid metabolism.J
    Clin Endocrinol Metab1995;80:1816-21.

  • 55. Poort SR, Rosendaal FR,
    Reitsma PH, Bertina RM. A common genetic variation in the
    3"-untranslated region of the prothrombin gene is associated
    with elevated plasma prothrombin levels and an increase in
    venous thrombosis. Blood 1996; 88: 3698-703.

  • 56. Porter JB. Oral contraceptives
    and nonfatal vascular disease — recent experience. Obstet
    Gynecol 1982; 59: 299-302.

  • 57. Prasad RN, Koh SC, Viegas OA,
    Ratnam SS. Effects on hemostasis after two-year use of low
    dose combined oral contraceptives with gestodene or
    levonorgestrel. Clin Appl Thromb Hemost 1999;
    5:60-70.

  • 58. Records Unit and Research
    Advisory Service of the Royal College of General Practioners.
    Oral contraception and thrombo-embolic disease. J R Coll Gen
    Pract 1967; 13: 267-79.

  • 59. Revenga Arranz F,
    García Bracamonte B, Quintana Martínez I,
    Rodríguez Peralto JL, Iglesias Díez L.
    Embolismo de colesterol con afectación cutánea:
    presentación de tres casos. Actas Dermosifiliogr
    1996;87:269-71

  • 60. Rintelen C, Mannhalter C,
    Ireland H, Lane DA, Knobl P, Lechner K, Pabinger I. Oral
    contraceptives enhance the risk of clinical manifestation of
    venous thrombosis at a young age in females homozygous for
    factor V Leiden. Br J Haematol 1996; 93: 487-90.

  • 61.  Ronde H, Bertina RM.
    Laboratory diagnosis of APC-resistance: a critical evaluation
    of the test and the development of diagnostic criteria.
    Thromb Haemost 1994; 72: 880-6.

  • 62. Rosendaal FR, Helmerhorst FM,
    Vandenbroucke JP. Oral contraceptives, hormone replacement
    therapy and thrombosis Thromb Haemost 2001;
    86:112-23.

  • 63. Rosendaal FR, Koster T,
    Vandenbroucke JP, Reitsma PH. High risk of thrombosis in
    patients homozygous for factor V Leiden (activated protein C
    resistance). Blood 1995; 85: 1504-8.

  • 64. Rosing J, Curvers J, Tans G.
    Oral contraceptives, thrombosis and haemostasis. Eur J Obstet
    Gynecol Reprod Biol 2001; 95:193-7.

  • 65. Rosing J, Middeldorp S,
    Curvers J, Christela M, Thomassen LG, Nicolaes GA, et al.
    Low-dose oral contraceptives and acquired resistance to
    activated protein C: a randomised cross-over study. Lancet
    1999; 354:2036-40.

  • 66. Rosing J, Tans G, Nicolaes GA,
    Thomanssen MC, Van der Oerle R, Van der Ploeg PM. Oral
    contraceptives and venous trombosis: different sensitivies to
    activated protein C in women using second-and third
    generation oral contraceptives. Br J Haematol 1997;
    97:233-8.

  • 67. Royal College of General
    Practioners" Oral Contraception Study. Oral contraceptives,
    venous thrombosis, and varicose veins. J R Coll Gen Pract
    1978; 28: 393-9.

  • 68. Sánchez R, Martinez O.
    Guía práctica en anticoncepción oral
    basada en la evidencia. Madrid: Emisa, 2003.

  • 69. Sapp AV, Lindbloom EJ. Do
    third-generation oral contraceptives (OCs) increase the risk
    of venous thrombosis? J Fam Pract 2001; 50:893.

  • 70. Sartwell PE, Masi AT, Arthes
    FG, Greene GR, Smith HE. Thromboembolism and oral
    contraceptives: an epidemiological case-control study. Am J
    Epidemiol 1969; 90: 365-80.

  • 71. Schlatterer K, Yassouiridis A,
    von Werder K, Polonia D, Kemper J, Stalla GKUn
    estudio de seguimiento a la estimación de la eficacia
    de una terapia de sustitución hormonal de
    género cruzado en pacientes
    transexuales. Archives of Sexual Behavior, 1998; 27:
    475-492…

  • 72. Seeger JD, Loughlin J, Eng PM,
    Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in
    women taking ethinylestradiol/ drospirenone and other oral
    contraceptives.Obstet Gynecol 2007; 110:587-93.

  • 73. Spitzer WO, Lewis MA,
    Heinemann LA, Thorogood M, MacRae KD. Third generation oral
    contraceptives and risk of venous thromboembolic disorders:
    an international case-control study. Transnational Research
    Group on Oral Contraceptives and the Health of Young Women.
    BMJ 1996; 312:83-8.

  • 74. Spitzer WO. El acetato de
    ciproterona con etinilestradiol como un factor de riesgo de
    tromboembolismo venoso: una evaluación
    epidemiológica. J Obstet Gynaecol Can. 2003
    Dec;25(12):1011-8.

  • 75. Stegeman BH, deBastos M,
    Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen
    T, Dekkers OM. Different combined oral contraceptives and the
    risk of venous thrombosis: systematic review and network
    meta-analysis. BMJ 2013; 347: f5298.

  • 76. Stolley PD, Tonascia JA,
    Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis
    with low-estrogen oral contraceptives. Am J Epidemiol 1975;
    102: 197-208.

  • 77. Tans G, Curvers J, Middeldorp
    S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized
    cross-over study on the effects of levonorgestrel- and
    desogestrel-containing oral contraceptives on the
    anticoagulant pathways. Thromb Haemost 2000;
    84:15-21.

  • 78. Tans G, van Hylckama Vlieg A,
    Thomassen MCLGD, Curvers J, Bertina RM, Rosing J, et al.
    Activated protein C resistance determined with a thrombin
    generation-based test predicts for venous thrombosis in men
    and women.Br J Haematol2003; 122:465-70.

  • 79. The Coronary Drug Project
    Research Group. The Coronary Drug Project. Findings leading
    to discontinuation of the 2.5-mg day estrogen group. JAMA
    1973; 226: 652-7.

  • 80. Thorogood M, Mann J, Murphy M,
    Vessey M. Risk factors for fatal venous thromboembolism in
    young women: a case-control study. Int J Epidemiol 1992; 21:
    48-52

  • 81. Van Haarst EP, Newling ARD,
    Gooren LJG, Asscheman H, PrengerDM
    metastásico carcinoma de próstata en un
    transexual de hombre a mujer. British Journal of
    Urology, 1998; 81: 776

  • 82. Van Kesteren P, Lips P, Gooren
    LJG, Asscheman H, Megens (1998) A largo plazo
    de seguimiento de la densidad mineral ósea en los
    transexuales tratados con hormonas del sexo
    opuesto. Clinical Endocrinology 48: 347-354

  • 83. Van Kesteren P, Megens JAJ,
    Asscheman H, efectos. Gooren LJG secundarios de
    la administración hormonal del sexo en
    transexuales. Clinical Endocrinology, 1997; 47:
    337-342

  • 84. Van Kesteren PJ, Asscheman H,
    Megens JA, Gooren LJ. Mortality and morbidity in transsexual
    subjects treated with cross-sex hormones. Clin Endocrinol
    (Oxf) 1997; 47: 337-42..

  • 85. Van Vliet HA, Frolich M,
    Christella M, Thomassen MCLGD, Doggen CJM, Rosendaal FR, et
    al. Association between sex hormone-binding globulin levels
    and activated protein C resistance in explaining the risk of
    thrombosis in users of oral contraceptives containing
    different progestogens.Hum Reprod 2005; 20:563-8.

  • 86. Van Vliet HA, Winkel TA, Noort
    I, Rosing J, Rosendaal FR. Prothrombotic changes in users of
    combined oral contraceptives containing drospirenone and
    cyproterone acetate.J Thromb Haemost 2004;
    2:2060-2.

  • 87. Vandenbroucke JP, Koster T,
    Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased
    risk of venous thrombosis in oral-contraceptive users who are
    carriers of factor V Leiden mutation. Lancet 1994; 344:
    1453-7.

  • 88. Vasilakis C, Jick SS, Jick H.
    The risk of venous thromboembolism in users of postcoital
    contraceptive pills. Contraception 1999; 59:
    79-83.

  • 89. Vessey MP, Doll R.
    Investigation of relation between use of oral contraceptives
    and thromboembolic disease. Br Med J 1968; 2:
    199-205.

  • 90. Vessey MP, Doll R.
    Investigation of relation between use of oral contraceptives
    and thromboembolic disease: a further report. Br Med J 1969;
    2: 651-7.

  • 91. World Health Organization
    Collaborative Study of Cardiovascular Disease and Steroid
    Hormone Contraception. Venous thromboembolic disease and
    combined oral contraceptives: results of international
    multicentre case-control study. Lancet 1995;
    346:1575-82.

  • 92. World Health Organization
    Collaborative Study of Cardiovascular Disease and Steroid
    Hormone Contraception. Effect of different progestagens in
    low oestrogen oral contraceptives on venous thromboembolic
    disease. Lancet 1995; 346:1582-8.

  • 93. World Health Organization.
    Cardiovascular disease and steroid hormone contraception.
    Report of a WHO Technical Report Series Geneva: WHO,
    1998

  • 94. Writing Group for the Women's
    Health Initiative Investigators. Risks and benefits of
    estrogen plus progestin in healthy postmenopausal women. JAMA
    2002;288:321-33.

  • 95. Yahyaoui R, Esteva I,
    Haro-Mora JJ, et al. Effect of long-term administration of
    cross-sex hormone therapy on serum and urinary acid in
    transsexual persons. J Clin Endocrinol Metab 2008;
    93:2230-3.

  •  

     

    Autor:

    Dra. Mireille Emmanuelle
    Brambila

    Higiene mental – Trastornos y enfermedades
    somáticas

    Mexicali Baja California

    México 2014

    Partes: 1, 2
     Página anterior Volver al principio del trabajoPágina siguiente 

    Nota al lector: es posible que esta página no contenga todos los componentes del trabajo original (pies de página, avanzadas formulas matemáticas, esquemas o tablas complejas, etc.). Recuerde que para ver el trabajo en su versión original completa, puede descargarlo desde el menú superior.

    Todos los documentos disponibles en este sitio expresan los puntos de vista de sus respectivos autores y no de Monografias.com. El objetivo de Monografias.com es poner el conocimiento a disposición de toda su comunidad. Queda bajo la responsabilidad de cada lector el eventual uso que se le de a esta información. Asimismo, es obligatoria la cita del autor del contenido y de Monografias.com como fuentes de información.

    Categorias
    Newsletter